Effects of Bariatric Surgery and Liraglutide on Weight Loss and Brain Function in Obesity
Official title: Effects of Bariatric Surgery and Pharmacological Therapy with Liraglutide on Motivational and Inhibitory Processes: Cognitive-Behavioral Markers of Long-Term Weight Loss. a Study on Patients with Obesity.
Run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · NCT06720246 · Data updated 2026-11-12
This study tests how bariatric surgery and the medication liraglutide affect weight loss and brain function in people with obesity.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 60 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio Academic / other |
| Locations | 1 site (Milan, Milan) |
| Status | Recruiting |
| Started | June 26, 2024 |
| Main results expected | May 1, 2027 |
| Study ends | May 1, 2027 |
| Registry record updated | December 11, 2024 |
| Trial ID | NCT06720246 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 20 to 60 with a BMI of 30 kg/m² or higher, scheduled for bariatric surgery or liraglutide treatment.
✕Probably not a fit
Patients with significant neurological or psychiatric disorders, or those with a BMI below 30 kg/m², may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research project investigates how bariatric surgery and liraglutide treatment influence cognitive-behavioral processes related to weight loss in obese patients. It focuses on two brain networks: the cue-reactivity network, which responds to food stimuli, and the cue-regulation network, which governs decision-making and inhibitory control. The study aims to identify cognitive-behavioral markers that predict treatment responses and how these processes are affected by feelings of satiety. Participants will be individuals already selected for surgery or liraglutide treatment, and their brain activity will be monitored to assess changes over time.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the cognitive-behavioral factors that contribute to long-term weight loss, leading to improved treatment strategies for obesity.
How similar studies have gone: While studies have explored the effects of bariatric surgery and GLP-1 agonists on weight loss, this specific focus on cognitive-behavioral markers and brain network activity is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects of any ethnicity, aged between 20 and 60 years. * BMI equal to or greater than 30 kg/m². * No history of neurological or psychiatric disorders, as confirmed through medical history and neuropsychological screening. * Signed informed consent and willingness to comply with all study procedures. * Patients scheduled for surgery, treatment with liraglutide, or a dietary regimen. Exclusion Criteria: * Previous diagnosis of significant neurological conditions (e.g., brain injury or dementia) or major psychiatric disorders. * Current or past psychopharmacological therapy, if prolonged. * BMI lower than 30 kg/m². * Lack of signed informed consent. * Severe medical conditions, including but not limited to: hypertension, significant cardiac disease, or other disorders that may compromise patient safety. * Confirmed pregnancy through self-report and/or breastfeeding.
Where it's running
-
IRCCS Ospedale Galeazzi-Sant'Ambrogio
Milan, Milan, Italy Recruiting
Study contacts
- Study coordinator: Eraldo Paulesu, MD
- Email: eraldo.paulesu@unimib.it
- Phone: +390264483748
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
IBI3046 in Overweight or Obesity
This study tests how safe and tolerable IBI3046 is in adults with overweight or obesity in China.
-
Sleep behavioral program for adolescents with overweight or obesity
This trial will test whether adding a sleep-focused behavioral program to usual weight treatment helps teens (13–17) with overweight or obesity who have poor sleep improve body composition and health markers.
-
Robotic versus laparoscopic conversion to RYGB for revision bariatric surgery
We will see if robotic surgery or laparoscopy leads to fewer postoperative complications for people having revision bariatric surgery converted to RYGB.
-
Bone health, vitamin D, weight, and fractures in children
See if blood markers (alkaline phosphatase, calcium, PTH, vitamin D), body weight, and calcium intake are linked to fractures in children aged 3–15 after low-energy trauma.
-
Efsubaglutide alfa for adults with overweight or obesity (SPARKLE)
This trial will test whether efsubaglutide alfa injections given weekly or every few weeks help adults with overweight or obesity lose weight safely.
-
Cardiovascular health in children and young adults with chronic conditions
This project will see if children and young adults (ages 6-25) with chronic health conditions show early signs of aging in large and small blood vessels using noninvasive imaging and clinical tests.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.